{"id":"NCT01661790","sponsor":"Chinese PLA General Hospital","briefTitle":"Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer","officialTitle":"Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2012-06","completion":"2012-10","firstPosted":"2012-08-10","resultsPosted":"2015-03-25","lastUpdate":"2015-03-25"},"enrollment":72,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Malignant Pleural Effusion"],"interventions":[{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]},{"type":"DRUG","name":"Cisplatin","otherNames":[]}],"arms":[{"label":"Bevacizumab & Cisplatin","type":"EXPERIMENTAL"},{"label":"Cisplatin","type":"ACTIVE_COMPARATOR"}],"summary":"To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).","primaryOutcome":{"measure":"Number of Participants With \"Complete Response\" and \"Partial Response\"","timeFrame":"from randomization, This treatment was given every two weeks,responses were made by biweekly","effectByArm":[{"arm":"Bevacizumab & Cisplatin","deltaMin":17,"sd":null},{"arm":"Cisplatin","deltaMin":2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":4},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":36},"commonTop":["Leucocytopenia"]}}